Alzheimer’s prevention seen promising as drug cures fail
Researchers are set to test drugs by Eli Lilly and other companies that may prevent Alzheimer’s disease after efforts to find a cure have been unsuccessful.
Pharmaceutical
Articles
Lilly stomach-cancer drug helps survival, study finds
Eli Lilly and Co. shares rose nearly 5 percent Monday morning after it said a study found that its experimental stomach-cancer drug helped patients with advanced disease live longer.
Lilly, Roche drugs chosen for Alzheimer’s prevention trial
Eli Lilly & Co.’s solanezumab and Roche Holding AG’s gantenerumab were selected for a long-term Alzheimer’s trial run by Washington University at St. Louis scientists seeking to block the disease’s symptoms.
Lilly shares rise on Alzheimer’s study results
Eli Lilly and Co.’s Alzheimer’s drug slowed cognitive decline 34 percent in patients with mild forms of the disease, according to an analysis of Lilly’s clinical trial data released Monday. Lilly’s share price jumped more than 5 percent on the news.
Lilly counting on diabetes products to challenge larger rivals
Eli Lilly and Co. is betting on a “broad” range of diabetes products including pills, insulins and a once-a-week treatment to take on bigger competitors, said Enrique Conterno, president of Lilly Diabetes.
Group aims to cut costs of late-stage drugs
You know things are bad in the fiercely competitive pharma industry when drugmakers start turning to each other for help. But that’s exactly what happened last week when 10 major drug companies—including Eli Lilly and Co.—joined forces to cut costs out of clinical trials.
Lilly’s Cialis gets European endorsement for new use
A European committee has endorsed the use of Eli Lilly and Co.'s erectile dysfunction drug Cialis to treat symptoms tied to an enlarged prostate.
Ten drugmakers team up to improve testing process
Pharmaceutical industry heavyweights, including Eli Lilly and Co., are teaming up to improve the way experimental drugs are tested so they can get approved, and reach patients, faster.
Two more clinical trials go against Lilly
In the midst of Eli Lilly and Co.’s surprisingly positive news about its experimental Alzheimer’s drug, the company suffered two other setbacks with former stars of its pipeline.
Lilly stops testing of experimental schizophrenia drug
Eli Lilly and Co. halted testing on an experimental treatment for schizophrenia after the company determined the drug was unlikely to show a benefit in patients.
Lilly’s Alzheimer’s finding triggers investor hope, doctor caution
While investors supported the sliver of promise offered when Eli Lilly and Co. said its Alzheimer’s drug may slow progression early in the disease, doctors weren’t as impressed, saying it could take years to find out for sure.
Lilly wins appeal upholding patent for Alimta cancer drug
Eli Lilly and Co. won a U.S. appeals court ruling that upholds the validity of a patent for the lung-cancer drug Alimta and blocks generic competition through 2017. Alimta generated $2.5 billion in sales last year.
Lilly’s Alzheimer’s drug trials show mixed results
Eli Lilly and Co.’s experimental Alzheimer’s drug failed to meet its primary goals in two separate clinical trials. However, when the results of both trials were combined, the drug appeared to have slowed the decline of cognition in some patients.
Lilly stock slips after competitors halt Alzheimer’s plans
Pfizer Inc., Johnson & Johnson and Elan Corp. are ending most plans to develop an Alzheimer’s drug after a second trial failure. Eli Lilly is developing a similar treatment.
Despite funding dip, IU bets on brains
The city that brought the world Prozac and other neuroscience drugs is doubling down on brain research with a new $52 million research center near Methodist Hospital.
McKesson to pay $151M to settle drug-pricing suit
Twenty-nine states, including Indiana, have reached a $151 million settlement in a lawsuit alleging one of the country's largest drug wholesalers inflated prices for hundreds of prescription drugs, officials said Friday.
Lilly’s quarterly profit falls, but tops analyst expectations
Eli Lilly and Co. reported second-quarter profit that fell less than analysts had expected. The company raised its outlook for the rest of the year.
Potential Alzheimer’s drug fails first of four key trials
Bapineuzumab is in a race with a similar product from Indianapolis-based Eli Lilly and Co. to become the first therapy to target a cause for Alzheimer’s, rather than just its symptoms.
Potential Lilly antipsychotic falls short in study
Eli Lilly and Co. said a potential treatment for acute schizophrenia failed in a late-stage study that compared patients taking the drug to those taking a placebo.
Lilly gets 6-month Cymbalta marketing extension
Eli Lilly and Co. said Friday that it has received an extra six months of marketing exclusivity on the antidepressant Cymbalta, its biggest selling drug. The extension could mean more than a billion dollars in sales for the Indianapolis drug maker.